nach oben

Erschienen in:

01.10.2012 | Original article

Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio

verfasst von: Simone Maurea, Alberto Cuocolo, Massimo Imbriaco, Teresa Pellegrino, Mario Fusari, Renato Cuocolo, Raffaele Liuzzi, Marco Salvatore

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

We compared metaiodobenzylguanidine (MIBG) uptake and magnetic resonance (MR) signal intensity ratio in differentiating benign and malignant disease in patients with pheochromocytoma or paraganglioma.

Methods

Eighteen patients (9 men, mean age 37 ± 8 years) with pheochromocytoma or paraganglioma underwent MR imaging and iodine-131 MIBG scintigraphy. MR signal intensity ratio was measured on T1 and T2-weighted images using region of interest analysis and intensity ratio of MIBG uptake was calculated for each tumor lesion on 48 h images.

Results

A total of 28 tumor lesions was analyzed of which 12 were benign and 16 malignant. MIBG uptake intensity ratio was significantly higher in malignant lesions compared to benign (5.2 ± 2.4 and 2.9 ± 1.4, respectively, p < 0.01). On the contrary, no significant difference in tumor size and MR signal intensity ratio between malignant and benign tumor lesions was observed.

Conclusions

In patients with pheochromocytoma or paraganglioma, iodine-131 MIBG uptake is able to differentiate between benign and malignant disease, while MR imaging is not useful for this purpose. The higher MIBG uptake observed in malignant lesions could reflect major tumor storage of catecholamines compared to benign lesions.

Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007;3:92–102.PubMedCrossRef

Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Pheochromocytoma. Lancet. 2005;366:665–75.PubMedCrossRef

Ra DeLellis, Lloyd RV, Heitz PU, et al. WHO classification of tumours-pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. p. 147–50.

Gao B, Kong F, Xu Z. Development of differential diagnosis for benign and malignant pheochromocytomas. Int J Urol. 2008;15:771–7.PubMedCrossRef

Blake MA, Kalra MK, Maher MM, Sahani DV, Sweeney AT, Mueller PR, et al. Pheochromocytoma: an imaging chameleon. Radiographics. 2004;24(Suppl 1):S87–99.PubMedCrossRef

Kann PH, Wirkus B, Behr T, Klose KJ, Meyer S. Endosonographic imaging of benign and malignant pheochromocytoma. J Clin Endocrinol Metab. 2004;89:1694–7.PubMedCrossRef

Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art of adrenal imaging. Radiographics. 2001;21:995–1012.PubMed

Maurea S, Caracò C, Castelli L, Filice S, Alfano B, Ruffolo F, et al. Magnetic resonance in the study of suprarenal neoplasms. Qualitative and quantitative analysis of signal intensity. Radiol Med. 1998;95:199–207.PubMed

Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14:587–99.PubMedCrossRef

10.

Nguyen HH, Proye CA, Carnaille B, Combemale F, Pattou FN, Huglo D. Tumor size: the only predictive factor for 131-I MIBG uptake in pheochromocytoma and paraganglioma. Austr N Z J Surg. 1999;69:350–3.CrossRef

11.

Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. 131-I MIBG scintigraphy for monitoring response to chemotherapy in malignant pheochromocytoma: comparison with urinary biochemical analysis. J Nucl Med. 1991;32:1044.

12.

Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, et al. The role of radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol. 1996;23:677–80.PubMedCrossRef

13.

van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. I-123 metaiodobenzylguanidine and In-111 octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685–93.PubMedCrossRef

14.

Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas and neuroblastomas: a histopathological comparison. J Nucl Med. 1987;28:973–8.PubMed

15.

McEwan AJ, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors. Sem Nucl Med. 1985;15:132–53.CrossRef

16.

Jacques S, Tobes MC, Sisson JC. Sodium dependency of uptake of nor-epinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res. 1987;47:3920–8.

17.

Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (I-131 MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20:648–58.PubMed

18.

Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, et al. High dose 131-I metaiodobenzylguaniodine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003;98:239–48.PubMedCrossRef

19.

Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant pheochromocytoma and paraganglioma. End Rel Cancer. 2007;14:569–85.CrossRef

20.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of F-18 fluoro-L-DOPA, F-18 fluoro-deoxyglucose, and F-18 fluorodopamine PET and I-123 MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757–67.PubMedCrossRef

21.

Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy. Radiology. 1987;165:89–93.PubMed

22.

Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131 metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993;34:173–9.PubMed

23.

van Gils AP, van Erkel AR, Falke THM, Pauwels EK. Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities. Eur J Nucl Med. 1994;21:239–53.PubMedCrossRef

Titel: Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio
verfasst von: Simone Maurea
Alberto Cuocolo
Massimo Imbriaco
Teresa Pellegrino
Mario Fusari
Renato Cuocolo
Raffaele Liuzzi
Marco Salvatore
Publikationsdatum: 01.10.2012
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 8/2012
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-012-0624-1

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2012

Novel method for quantitative evaluation of cardiac amyloidosis using 201TlCl and 99mTc-PYP SPECT

Comparison of diagnostic ability between 99mTc-MDP bone scan and 18F-FDG PET/CT for bone metastasis in patients with small cell lung cancer

F-18 fluorodeoxyglucose uptake and water-perfusable tissue fraction in assessment of myocardial viability

Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma

Correlation between neuropsychological tests and hypoperfusion in MCI patients: anatomical labeling using xjView and Talairach Daemon Software

Bronchial anthracofibrosis: a potential false-positive finding on F-18 FDG PET